Daiichi Sankyo Company
- All
- News
- Videos
-
"Will Send You To Jail," Ranbaxy Singh Brothers Told By Court: 10 Points
The former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh, were told by the Supreme Court today that they could go to jail for disobeying orders to pay dues to Japanese firm Daiichi Sankyo. "We will go into the issue - why you violated our orders. We will send you to jail. We have given you ...
-
Sun Pharma's Open Offer Fair: Zenotech Panel
A Zenotech Laboratories-formed committee of independent directors has termed Sun Pharmaceutical Industries' open offer worth Rs 20.23 crore to acquire a little over 28 per cent stake in the company as "fair and reasonable".
-
Sun Pharma Gives Marching Orders to 18 Top-Ranking Officers: Report
Sun Pharma, India's largest drugmaker by sales, has reportedly asked 18 of its top executives to leave the company. The high-ranking executives earlier worked with Ranbaxy Labs, the company Sun Pharma acquired from Japan's Daiichi Sankyo in April 2014.
-
Dilip Shanghvi Did Not Buy Daiichi Sankyo's Shares: Sun Pharma
The company was clarifying on speculations that Mr Sanghvi, who holds 9.61 per cent stake in Sun Pharma, had bought shares when Daiichi Sankyo exited from the Indian firm.
-
Wipro, Yes Bank, Natco Pharma in Focus Today
The Nifty is likely to open lower on Wednesday tracking lacklustre cues from the global markets. Foreign investors bought shares worth Rs 17,489 crore on Tuesday, but this amount includes purchases of Sun Pharma shares sold by Japan's Daiichi Sankyo, which exited the company.
-
Sun Pharma Slumps Over 10% as Daiichi Exits
Japan's Daiichi Sankyo Company Ltd is selling shares worth up to $3.6 billion in Sun Pharmaceutical Industries.
-
Japan's Daiichi Sankyo To Sell Up To $3.6 Billion Sun Pharma Stake: Report
The Japanese company is selling its 8.9 per cent stake in Sun Pharma, India's largest drugmaker by sales, via block deals on the Indian exchanges, said the person, who declined to be named as he was not authorised to speak to the media.
-
2014: Pharma Deals Worth Billions, Fines Worth Millions
It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.
-
Ranbaxy up; Nod to Generic Version of Novartis Drug
Ranbaxy Laboratories rose 5.8 per cent in early trading after the US Food and Drug Administration (FDA) on Thursday said it has approved the company's generic version of Novartis AG's blood pressure drug Diovan.
-
Supreme Court Asks Andhra High Court to Decide on Ranbaxy-Sun Pharma Merger
Hearing appeals filed by Sun Pharmaceutical, Ranbaxy Laboratories and Daiichi Sankyo Company against HC interim order, a bench of justices B S Chauhan and A K Sikri asked the HC to decide the issue and posted the case for hearing on May 27.
-
Crisil reaffirms 'A1+' rating on Ranbaxy's bank facilities
Rating agency Crisil has reaffirmed its 'A1+' rating on bank facilities of Ranbaxy Laboratories after Sun Pharmaceutical Industries' announcement to acquire a 100 per cent stake in it.
-
Sun Pharma may phase-out Ranbaxy-branded drugs in US: report
Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments as part of a strategy to turn around the company that is being bought from Japan's Daiichi Sankyo. The brand is likely to continue to be present in other markets, the sources said.
-
Sun Pharma to acquire Ranbaxy in $4 billion all-stock deal
Mumbai-based Sun Pharma will acquire troubled Indian drug maker Ranbaxy in a US$ 4 billion all-stock transaction, the company said in a statement on Monday.
-
Ranbaxy shares fall 4% after US drug recall
Ranbaxy confirmed the recall of select batches of the drug, a generic version of Pfizer Inc's Lipitor, but said the company had not received any product complaints.
-
Ranbaxy shares slump; US regulator raises concerns about India plants
All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.
-
"Will Send You To Jail," Ranbaxy Singh Brothers Told By Court: 10 Points
The former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh, were told by the Supreme Court today that they could go to jail for disobeying orders to pay dues to Japanese firm Daiichi Sankyo. "We will go into the issue - why you violated our orders. We will send you to jail. We have given you ...
-
Sun Pharma's Open Offer Fair: Zenotech Panel
A Zenotech Laboratories-formed committee of independent directors has termed Sun Pharmaceutical Industries' open offer worth Rs 20.23 crore to acquire a little over 28 per cent stake in the company as "fair and reasonable".
-
Sun Pharma Gives Marching Orders to 18 Top-Ranking Officers: Report
Sun Pharma, India's largest drugmaker by sales, has reportedly asked 18 of its top executives to leave the company. The high-ranking executives earlier worked with Ranbaxy Labs, the company Sun Pharma acquired from Japan's Daiichi Sankyo in April 2014.
-
Dilip Shanghvi Did Not Buy Daiichi Sankyo's Shares: Sun Pharma
The company was clarifying on speculations that Mr Sanghvi, who holds 9.61 per cent stake in Sun Pharma, had bought shares when Daiichi Sankyo exited from the Indian firm.
-
Wipro, Yes Bank, Natco Pharma in Focus Today
The Nifty is likely to open lower on Wednesday tracking lacklustre cues from the global markets. Foreign investors bought shares worth Rs 17,489 crore on Tuesday, but this amount includes purchases of Sun Pharma shares sold by Japan's Daiichi Sankyo, which exited the company.
-
Sun Pharma Slumps Over 10% as Daiichi Exits
Japan's Daiichi Sankyo Company Ltd is selling shares worth up to $3.6 billion in Sun Pharmaceutical Industries.
-
Japan's Daiichi Sankyo To Sell Up To $3.6 Billion Sun Pharma Stake: Report
The Japanese company is selling its 8.9 per cent stake in Sun Pharma, India's largest drugmaker by sales, via block deals on the Indian exchanges, said the person, who declined to be named as he was not authorised to speak to the media.
-
2014: Pharma Deals Worth Billions, Fines Worth Millions
It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.
-
Ranbaxy up; Nod to Generic Version of Novartis Drug
Ranbaxy Laboratories rose 5.8 per cent in early trading after the US Food and Drug Administration (FDA) on Thursday said it has approved the company's generic version of Novartis AG's blood pressure drug Diovan.
-
Supreme Court Asks Andhra High Court to Decide on Ranbaxy-Sun Pharma Merger
Hearing appeals filed by Sun Pharmaceutical, Ranbaxy Laboratories and Daiichi Sankyo Company against HC interim order, a bench of justices B S Chauhan and A K Sikri asked the HC to decide the issue and posted the case for hearing on May 27.
-
Crisil reaffirms 'A1+' rating on Ranbaxy's bank facilities
Rating agency Crisil has reaffirmed its 'A1+' rating on bank facilities of Ranbaxy Laboratories after Sun Pharmaceutical Industries' announcement to acquire a 100 per cent stake in it.
-
Sun Pharma may phase-out Ranbaxy-branded drugs in US: report
Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments as part of a strategy to turn around the company that is being bought from Japan's Daiichi Sankyo. The brand is likely to continue to be present in other markets, the sources said.
-
Sun Pharma to acquire Ranbaxy in $4 billion all-stock deal
Mumbai-based Sun Pharma will acquire troubled Indian drug maker Ranbaxy in a US$ 4 billion all-stock transaction, the company said in a statement on Monday.
-
Ranbaxy shares fall 4% after US drug recall
Ranbaxy confirmed the recall of select batches of the drug, a generic version of Pfizer Inc's Lipitor, but said the company had not received any product complaints.
-
Ranbaxy shares slump; US regulator raises concerns about India plants
All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.
